Matthieu Grollemund is a Private Equity M&A partner and a member of the Firm’s Private Capital industry group.
Triple-qualified in French, U.S., and U.K. law, Matthieu has over two decades of experience advising on complex cross-border transactions in highly regulated sectors, including technology and healthcare.
Matthieu advises private equity sponsors, venture capital firms, public and private companies, as well as boards and special committees, on high-stakes investments, public and private M&A transactions, IPOs, and both negotiated and contested acquisitions.
Education
- University of Paris I, Pantheon Sorbonne, Corporate Law
- ESCP Paris, M.B.A.
Admissions & Qualifications
- Paris
- Solicitor of England and Wales
- Licensed as a Foreign Legal Consultant, New York
Awards & Recognition
Europe Most Innovative Lawyers – Financial Times, 2016 & 2022
Ranked in Corporate M&A (France) – Chambers Global, 2021
Ranked in Private Equity: Venture Capital (France) – Chambers Europe, 2020
Option Droit & Affaires: “LBO transactions over 300 M EUR », 2020-2021
Languages
- English
- French
- German
Matters
Recent experience includes advising:
- Advised on numerous major French Tech transactions (Doctolib, Mirakl, Ynsect, Ledger, ManoMano, Contentsquare, Sorare, Exotec, Blablacar, Dataiku, FarFetch, Back Market, PayFit, Lydia, Criteo)*
- Advised on multiple AI, energy or Infratech deals, notably:
- Ardian on the buyback of Akuo energy*
- Verkor on its gigafactory of €2bn*
- DataOne, Goodman and hyperscalers on +€5bn Datacenters investments*
- Advised on a number of IPO and international offerings (Planisware, AAA, Criteo, Navya, Farfetch)*
- Advised numerous tender of offers and Public M&A:
- Zimmer Biomet on Medtech*
- Medtronic on Medicrea*
- Stryker on Vexim*
- Aptar on Voluntis*
- Tencent on the acquisition of a minority interest in Ubisoft from Vivendi*
- ADM in the acquisition of Neovia from Invivo and Eurazeo for €1.4bn*
*Aforementioned matters handled at prior firm.